



Hilton Liverpool City Centre

3-5 April 2017

PROVISIONAL PROGRAMME

MONDAY – 3rd April 2017			
09:00	Registration open for CEP and Congress Delegates		
Continuing Education Programme			
Mixtures Toxicity and Risk Assessment			
Chair: HSE (Ian Dewhurst or other) - Introduction: What is the concern about mixtures?			
10:00 – 10:45	In silico prediction & screening for mixture toxicity Mark Cronin (Liverpool John Moore's University, UK)		
10:45 – 11:30	AOPs & mixtures Angelo Moretto (University of Milan, Italy)		
11:30 – 12:00	Refreshments		
12:00 – 12:45	Case study: endocrine disruption, mammalian & invertebrate effects Richard Green (Dow AgroSciences, UK)		
12:45 – 13.30	Lunch and Trade Exhibition		
Congress Programme			
13:30 – 13:45	Welcome by the BTS President Dr Ernie Harpur (Newcastle University, UK)		
13:45 – 14:45	Plenary Lecture: The importance of mechanistic science to toxicology Professor Andy Smith (MRC Toxicology Unit, UK) <i>Chair: Dr Ernie Harpur (Newcastle University, UK)</i>		
14:45 – 17:15	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> Symposium 1: Drug Metabolism and Transporters <i>Chairs: Professor Marion MacFarlane (MRC Toxicology Unit, UK)</i> <i>Dr Muireann Coen (Imperial College London, UK)</i> </td> <td style="width: 50%; vertical-align: top;"> Symposium 2: Endocrine Disruption in Toxicology & Pathology <i>Chairs: Dr Carol Courage (Unilever, UK)</i> <i>Dr Catherine Ross (Covance UK)</i> </td> </tr> </table>	Symposium 1: Drug Metabolism and Transporters <i>Chairs: Professor Marion MacFarlane (MRC Toxicology Unit, UK)</i> <i>Dr Muireann Coen (Imperial College London, UK)</i>	Symposium 2: Endocrine Disruption in Toxicology & Pathology <i>Chairs: Dr Carol Courage (Unilever, UK)</i> <i>Dr Catherine Ross (Covance UK)</i>
Symposium 1: Drug Metabolism and Transporters <i>Chairs: Professor Marion MacFarlane (MRC Toxicology Unit, UK)</i> <i>Dr Muireann Coen (Imperial College London, UK)</i>	Symposium 2: Endocrine Disruption in Toxicology & Pathology <i>Chairs: Dr Carol Courage (Unilever, UK)</i> <i>Dr Catherine Ross (Covance UK)</i>		
14:45 – 15:15	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> Biological consequences of bioactivation Dr Ian Cople (MRC Centre for Drug Safety Science, UK) </td> <td style="width: 50%; vertical-align: top;"> EDCs the background, concerns and future perspectives Professor Juliette Legler (Brunel University London, UK) </td> </tr> </table>	Biological consequences of bioactivation Dr Ian Cople (MRC Centre for Drug Safety Science, UK)	EDCs the background, concerns and future perspectives Professor Juliette Legler (Brunel University London, UK)
Biological consequences of bioactivation Dr Ian Cople (MRC Centre for Drug Safety Science, UK)	EDCs the background, concerns and future perspectives Professor Juliette Legler (Brunel University London, UK)		
15:15 – 15:45	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> Reactive metabolites and toxicology Dr Emre M Isin (AstraZeneca, Sweden) </td> <td style="width: 50%; vertical-align: top;"> Strengths and limitations of current testing Dr Miriam Jacobs (Public Health England, UK) </td> </tr> </table>	Reactive metabolites and toxicology Dr Emre M Isin (AstraZeneca, Sweden)	Strengths and limitations of current testing Dr Miriam Jacobs (Public Health England, UK)
Reactive metabolites and toxicology Dr Emre M Isin (AstraZeneca, Sweden)	Strengths and limitations of current testing Dr Miriam Jacobs (Public Health England, UK)		
15:45 – 16:15	<i>Refreshments and Trade Exhibition</i>		
16:15 – 16:45	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> Role of multidrug transporters in drug toxicity Dr Hendrik W Van Veen (University of Cambridge, UK) </td> <td style="width: 50%; vertical-align: top;"> The pathology associated with endocrine disrupting chemicals Dr Aswin Menke (Triskelion B.V. A TNO company, The Netherlands) </td> </tr> </table>	Role of multidrug transporters in drug toxicity Dr Hendrik W Van Veen (University of Cambridge, UK)	The pathology associated with endocrine disrupting chemicals Dr Aswin Menke (Triskelion B.V. A TNO company, The Netherlands)
Role of multidrug transporters in drug toxicity Dr Hendrik W Van Veen (University of Cambridge, UK)	The pathology associated with endocrine disrupting chemicals Dr Aswin Menke (Triskelion B.V. A TNO company, The Netherlands)		
16:45 – 17:15	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> Pharmacogenomics and epigenetic alteration of membrane transporters Professor Dr. Matthias Schwab (Institut für Klinische Pharmakologie, Germany) </td> <td style="width: 50%; vertical-align: top;"> Future approaches to risk assessment of EAC Matt Dent (Unilever, UK) </td> </tr> </table>	Pharmacogenomics and epigenetic alteration of membrane transporters Professor Dr. Matthias Schwab (Institut für Klinische Pharmakologie, Germany)	Future approaches to risk assessment of EAC Matt Dent (Unilever, UK)
Pharmacogenomics and epigenetic alteration of membrane transporters Professor Dr. Matthias Schwab (Institut für Klinische Pharmakologie, Germany)	Future approaches to risk assessment of EAC Matt Dent (Unilever, UK)		
17:15 – 18:45	BTS AGM		
18:45	Drinks Reception		
19:30 onwards	Society Meetings: Early Career Networking Quiz, BTS Speciality Section Networking, BTS Executive Meeting (details to follow)		

Hilton Liverpool City Centre
3-5 April 2017
PROVISIONAL PROGRAMME

TUESDAY – 4th April 2017			
08:00	Registration opens		
08:00 – 08:40	BTS Ambassadors Breakfast		
08:40 – 09:25	<p>Early Career Investigator Prize Lecture: Tbc</p> <p><i>Chair: Professor Tim Gant (Public Health England Centre for Radiation, Chemical and Environmental Hazards, UK)</i></p>		
09:30 – 12:30	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <p>Symposium 3: Advanced Therapy Medicinal Products (ATMPs): Scientific and Regulatory Challenges (<i>BTS Regulatory Toxicology Speciality Section</i>)</p> <p><i>Chairs: Dr Henry Stemplewski (Medicines and Healthcare products Regulatory Agency, UK)</i> <i>Dr John Thompson (Cardiff University, UK)</i></p> </td> <td style="width: 50%; vertical-align: top;"> <p>Symposium 4: Complex <i>in vitro</i> Models (and other Non-animal approaches) to drive Exposure-based Risk Assessment (<i>National Centre for the Replacement, Refinement & Reduction of Animals in Research & BTS Discovery Toxicology Speciality Section</i>)</p> <p><i>Chairs: Dr Peter Newham (AstraZeneca, UK)</i> <i>Dr Fiona Sewell, NC3Rs, UK)</i></p> </td> </tr> </table>	<p>Symposium 3: Advanced Therapy Medicinal Products (ATMPs): Scientific and Regulatory Challenges (<i>BTS Regulatory Toxicology Speciality Section</i>)</p> <p><i>Chairs: Dr Henry Stemplewski (Medicines and Healthcare products Regulatory Agency, UK)</i> <i>Dr John Thompson (Cardiff University, UK)</i></p>	<p>Symposium 4: Complex <i>in vitro</i> Models (and other Non-animal approaches) to drive Exposure-based Risk Assessment (<i>National Centre for the Replacement, Refinement & Reduction of Animals in Research & BTS Discovery Toxicology Speciality Section</i>)</p> <p><i>Chairs: Dr Peter Newham (AstraZeneca, UK)</i> <i>Dr Fiona Sewell, NC3Rs, UK)</i></p>
<p>Symposium 3: Advanced Therapy Medicinal Products (ATMPs): Scientific and Regulatory Challenges (<i>BTS Regulatory Toxicology Speciality Section</i>)</p> <p><i>Chairs: Dr Henry Stemplewski (Medicines and Healthcare products Regulatory Agency, UK)</i> <i>Dr John Thompson (Cardiff University, UK)</i></p>	<p>Symposium 4: Complex <i>in vitro</i> Models (and other Non-animal approaches) to drive Exposure-based Risk Assessment (<i>National Centre for the Replacement, Refinement & Reduction of Animals in Research & BTS Discovery Toxicology Speciality Section</i>)</p> <p><i>Chairs: Dr Peter Newham (AstraZeneca, UK)</i> <i>Dr Fiona Sewell, NC3Rs, UK)</i></p>		
09:30 – 10:00	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <p>ATMPs: where are we now? Alison Wilson (Consultant, Cell Data Services, UK)</p> </td> <td style="width: 50%; vertical-align: top;"> <p>ToxCast and the use of human relevant <i>in vitro</i> exposures: incorporating high-throughput exposure predictions with chemical toxicity testing data to provide more human relevant risk-based assessments Dr Rusty Thomas (US Environmental Protection Agency, USA)</p> </td> </tr> </table>	<p>ATMPs: where are we now? Alison Wilson (Consultant, Cell Data Services, UK)</p>	<p>ToxCast and the use of human relevant <i>in vitro</i> exposures: incorporating high-throughput exposure predictions with chemical toxicity testing data to provide more human relevant risk-based assessments Dr Rusty Thomas (US Environmental Protection Agency, USA)</p>
<p>ATMPs: where are we now? Alison Wilson (Consultant, Cell Data Services, UK)</p>	<p>ToxCast and the use of human relevant <i>in vitro</i> exposures: incorporating high-throughput exposure predictions with chemical toxicity testing data to provide more human relevant risk-based assessments Dr Rusty Thomas (US Environmental Protection Agency, USA)</p>		
10:00 – 10:30	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <p>ATMPs: Non-clinical development Dr Michaela Sharpe (Cell & Gene Therapy Catapult, UK)</p> </td> <td style="width: 50%; vertical-align: top;"> <p>Application of 3D and liver models in drug discovery phase toxicology Dr Tracy Walker (GlaxoSmithKline, UK)</p> </td> </tr> </table>	<p>ATMPs: Non-clinical development Dr Michaela Sharpe (Cell & Gene Therapy Catapult, UK)</p>	<p>Application of 3D and liver models in drug discovery phase toxicology Dr Tracy Walker (GlaxoSmithKline, UK)</p>
<p>ATMPs: Non-clinical development Dr Michaela Sharpe (Cell & Gene Therapy Catapult, UK)</p>	<p>Application of 3D and liver models in drug discovery phase toxicology Dr Tracy Walker (GlaxoSmithKline, UK)</p>		
10:30 – 11:00	<i>Refreshments and Trade Exhibition</i>		
11:00 – 11:30	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <p>Clinical development of ATMPs Dr Bridget Heelan (Parexel International Corporation, UK)</p> </td> <td style="width: 50%; vertical-align: top;"> <p>Developing dynamic organ on chip models Dr Sinbad Sweeney (AstraZeneca, UK)</p> </td> </tr> </table>	<p>Clinical development of ATMPs Dr Bridget Heelan (Parexel International Corporation, UK)</p>	<p>Developing dynamic organ on chip models Dr Sinbad Sweeney (AstraZeneca, UK)</p>
<p>Clinical development of ATMPs Dr Bridget Heelan (Parexel International Corporation, UK)</p>	<p>Developing dynamic organ on chip models Dr Sinbad Sweeney (AstraZeneca, UK)</p>		
11:30 – 12:00	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <p>Regulatory challenges Dr Jimmy McBlane (Medicines and Healthcare products Regulatory Agency, UK)</p> </td> <td style="width: 50%; vertical-align: top;"> <p>The comprehensive <i>in vitro</i> pro-arrhythmia assay (CIPA): practical and scientific considerations in implementation Dr Jean-Pierre Valentin (UCB Pharma, Belgium)</p> </td> </tr> </table>	<p>Regulatory challenges Dr Jimmy McBlane (Medicines and Healthcare products Regulatory Agency, UK)</p>	<p>The comprehensive <i>in vitro</i> pro-arrhythmia assay (CIPA): practical and scientific considerations in implementation Dr Jean-Pierre Valentin (UCB Pharma, Belgium)</p>
<p>Regulatory challenges Dr Jimmy McBlane (Medicines and Healthcare products Regulatory Agency, UK)</p>	<p>The comprehensive <i>in vitro</i> pro-arrhythmia assay (CIPA): practical and scientific considerations in implementation Dr Jean-Pierre Valentin (UCB Pharma, Belgium)</p>		
12:00 – 12:30	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> <p>Royal College of Pathologists awareness: Specialty Advisory Committee (Toxicology) and the examination system Dr David Woolley (ForthTox, UK) and Professor Heather Wallace (University of Aberdeen, UK)</p> </td> <td style="width: 50%; vertical-align: top;"> <p>The importance of exposure considerations in safety assessment and the use of PBPK modelling to increase the utility of <i>in vitro</i> data Dr Carl Westmoreland (Unilever, UK)</p> </td> </tr> </table>	<p>Royal College of Pathologists awareness: Specialty Advisory Committee (Toxicology) and the examination system Dr David Woolley (ForthTox, UK) and Professor Heather Wallace (University of Aberdeen, UK)</p>	<p>The importance of exposure considerations in safety assessment and the use of PBPK modelling to increase the utility of <i>in vitro</i> data Dr Carl Westmoreland (Unilever, UK)</p>
<p>Royal College of Pathologists awareness: Specialty Advisory Committee (Toxicology) and the examination system Dr David Woolley (ForthTox, UK) and Professor Heather Wallace (University of Aberdeen, UK)</p>	<p>The importance of exposure considerations in safety assessment and the use of PBPK modelling to increase the utility of <i>in vitro</i> data Dr Carl Westmoreland (Unilever, UK)</p>		
12:30 – 13:30	<i>Lunch and Trade Exhibition</i>		
13:30 – 14:30	<p>Barnes Prize Lecture: Understanding Drug Toxicity - From man to molecule and back again Professor Kevin Park (University of Liverpool, UK)</p> <p><i>Chair: Dr Ernie Harpur (Newcastle University, UK)</i></p>		



Hilton Liverpool City Centre

3-5 April 2017

PROVISIONAL PROGRAMME

14:30 – 15:00	<i>Refreshments and Trade Exhibition</i>	
15:00 – 17:00	<p>Oral Communications</p> <p><i>Chair: Jason Manton (Syngenta, UK)</i></p>	<p>Study Director/Study Monitor Workshop</p> <p><i>Chairs: Graham Morgan (ICON, UK)</i> <i>Sean O'Halloran (Covance, UK)</i></p> <ul style="list-style-type: none"> • Inclusion of CNS Safety Pharmacology endpoints in repeat-dose toxicity studies Dr Will Redfern (AstraZeneca, UK) • Use of a cross over study design for rodent respiratory assessment using whole body plethysmography Ms Louise Coleman (Charles River Laboratories, UK) • The Role of a Study Monitor – Revisited Graham Morgan (ICON plc, UK) • Is there, or should there be a difference in the way Study Directors conduct and report studies for pharmaceuticals compared with chemicals? Narinder Barraclough (Covance, UK)
17:00 – 18:30	Poster Session	
19:00 – 19:30	Pre-Dinner Drinks Reception	
19:30 – Late	Congress Dinner	

Hilton Liverpool City Centre
3-5 April 2017
PROVISIONAL PROGRAMME

WEDNESDAY – 5th April 2017		
08:00	Registration opens	
08:40 – 09:40	Early Career Bursary Oral Communications <i>Chair: Dr Tina Mehta (Dow Agrosciences, UK)</i>	
09:45 – 12:15	Symposium 5: Toxicology and the Human Microbiome <i>Chair: Professor Tim Gant (Public Health England Centre for Radiation, Chemical and Environmental Hazards, UK)</i>	Symposium 6: Adverse Outcome Pathways (AOP)- based Approaches to Safety Assessment (<i>Royal Society of Chemistry Toxicology group & BTS</i>) <i>Chairs: Dr Richard Currie (Syngenta, UK) Dr Paul Russell (Unilever, UK)</i>
09:45 – 10:15	The gut microbiome in health and disease Dr Alan Walker (University of Aberdeen, UK)	Adverse Outcome Pathways - from research to regulation (an overview) Dr Stephen Edwards (US Environmental Protection Agency, USA)
10:15 – 10:45	Microbiome and the metabolome Professor Elaine Holmes (Imperial College London, UK)	AOPs to support in silico predictions: the link from chemistry to adverse effects Dr Timothy Allen (University of Cambridge, UK)
10:45 – 11:15	<i>Refreshments and Trade Exhibition</i>	
11:15 – 11:45	Environmental exposures, toxicology and the microbiome Professor Tom Van de Wiele (Ghent University, Belgium)	Ecotoxicology: the utility of AOPs in safety assessment Richard Green (Dow Agroscience, UK)
11:45 – 12:15	Microbiome and xenobiotic metabolism Dr Andrew Patterson (Pennsylvania State University, USA)	Application of pathway modelling to drug induced liver injury Professor Mathieu Vinken (Vrije Universiteit Brussel, Belgium)
12:15 – 13:00	<i>Lunch and Trade Exhibition</i>	
13:00 – 14:00	ASCEPT Lecture: Pesticides: Translating mechanism to clinical practice Professor Andrew Dawson (University of Sydney, Australia) <i>Chair: Professor Shirley Price (University of Surrey, UK)</i>	
14:00 – 15:00	Hot Topic Lecture: E-cigarettes – are there toxicological concerns? Dr Tim Marczylo (Public Health England, UK) <i>Chair: Professor Tim Gant (Public Health England Centre for Radiation, Chemical and Environmental Hazards, UK)</i>	
15:00	<i>Close of Congress</i>	